A more effective and better-tolerated treatment for chronic myeloid leukemia (CML) could improve quality of life for people living with the disease. A new study led by Adelaide University and the South Australian Health and Medical Research Institute (SAHMRI) has provided the first direct evidence that a targeted therapy can rapidly and consistently suppress the molecular signals that drive CML.